MOB:+8617734410222

GW501516
GW501,516.svg
Clinical data
Pregnancy
category
  • N/A
Routes of
administration
oral
ATC code
  • none
Legal status
Legal status
  • AU: Scheduled as illegal from June 2018
  • UK: Unscheduled
  • US: Unscheduled
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
ChEMBL
Chemical and physical data
Formula C21H18F3NO3S2
Molar mass 453.498 g/mol g·mol−1
3D model (JSmol)

GW501516 (also known as GW-501,516GW1516GSK-516, Cardarine, and on the black market as Endurobol[1]) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s, was entered into clinical development as a drug candidate for metabolic diseases and cardiovascular diseases, and was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.[2]

In 2007, research was published showing that high doses of GW501516 given to mice dramatically improved their physical performance; the work was widely discussed in popular media, and led to a black market for the drug candidate and to its abuse by athletes as a doping agent. The World Anti-Doping Agency (WADA) developed a test for GW501516 and other related chemicals and added them to the prohibited list in 2009; it has issued additional warnings to athletes that GW501516 is not safe



           

Copyright © 2014-2024 HEBEI SHUOXI BIOTECHNOLOGY CO., LTD. Power by DedeCms